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Abstract
T-LAK-originated protein kinase (TOPK) overexpression is a feature of multiple cancers, yet is absent from most
phenotypically normal tissues. As such, TOPK expression profiling and the development of TOPK-targeting pharmaceutical
agents have raised hopes for its future potential in the development of targeted therapeutics. Results presented in this paper
confirm the value of TOPK as a potential target for the treatment of solid tumours, and demonstrate the efficacy of a TOPK
inhibitor (OTS964) when used in combination with radiation treatment. Using H460 and Calu-6 lung cancer xenograft
models, we show that pharmaceutical inhibition of TOPK potentiates the efficacy of fractionated irradiation. Furthermore,
we provide in vitro evidence that TOPK plays a hitherto unknown role during S phase, showing that TOPK depletion
increases fork stalling and collapse under conditions of replication stress and exogenous DNA damage. Transient
knockdown of TOPK was shown to impair recovery from fork stalling and to increase the formation of replication-
associated single-stranded DNA foci in H460 lung cancer cells. We also show that TOPK interacts directly with CHK1 and
Cdc25c, two key players in the checkpoint signalling pathway activated after replication fork collapse. This study thus
provides novel insights into the mechanism by which TOPK activity supports the survival of cancer cells, facilitating
checkpoint signalling in response to replication stress and DNA damage.
Introduction
Owing to the uncontrolled and deregulated cell growth in
tumours, endogenous replication stress is a common feature
of cancer cells [1]. Oncogene activation can lead to the
deregulation of DNA replication through various mechan-
isms, including changes in origin licencing and firing, fork
progression or cell-cycle timing [2, 3]. Exogenous sources of
replication stress include DNA damage (by ionising or UV
radiation, topoisomerase inhibitors and secondary structure
inducers) or substrate depletion (exhaustion of nucleotide
pools, histones and DNA binding proteins, and inhibition of
replication machinery) [2]. Replication stress impairs DNA
transcription and impairs cell-cycle checkpoint control and
can ultimately cause genomic damage in the form of localised
DNA lesions [2, 3]. Consequently, cancer cells develop
selective resistance to oncogene-driven replication stress,
which enables them to tolerate higher levels of exogenous
DNA damage than untransformed cells [1]. As a consistent
and specific feature of tumorigenesis, replication stress
represents a potential target for selective cancer therapy [4, 5].
ATR-CHK1-Cdc25 signalling is the predominant reg-
ulatory mechanism activated as a consequence of DNA
damage sustained during active cellular replication [6].
CHK1 activation triggers a multi-stage signalling cascade,
which stabilises stalled replication forks, regulates origin
firing and delays G2/M progression by Cdk1/2 activation
until such time as the defect is resolved [7]. When activation
of the intra-S and G2/M checkpoint is impaired by inhibi-
tion of ATR-CHK1-Cdc25 signalling, under-replicated and
damaged DNA progresses from G2 into mitosis, producing
mitotic abnormalities and dysregulated cytokinesis [8].
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T-LAK-originated protein kinase (TOPK) is a recently
characterised mitogen-activated protein kinase, which is
upregulated in many subtypes of cancer. As overexpression
is associated with tumorigenic tissues, TOPK is a potential
biomarker and selective target for cancer treatment, with a
number of inhibitory agents currently in preclinical devel-
opment. Although its precise role in malignant transfor-
mation is currently unknown, the phenotype for TOPK
suppression in cancer cells is cell cycle related, causing G2/
M checkpoint failure leading to cytokinesis defects, multi-
polar nuclei and enhanced apoptotic cell death occurring
48–72 h following DNA damage [9–11]. We have pre-
viously shown that TOPK depletion increases radio-
sensitisation [10], however, a potential mechanism for
TOPK’s role in the protection against exogenous and
endogenous DNA damage is still unclear.
TOPK’s function is thought to be largely confined to
mitosis. Here we show that TOPK also plays an important
role in S-phase progression and that depleting or inhibiting
TOPK weakens resistance to radiation-induced DNA
damage by sensitising tumour cells to replication stress. Our
investigations demonstrate that TOPK directly interacts
with CHK1 and Cdc25C during cell-cycle progression, and
that suppression of TOPK leaves cancer cells vulnerable to
DNA damage during CHK1-mediated checkpoint activa-
tion. We show that this phenotype can be exploited to
improve the outcome of radiotherapy treatments with TOPK
inhibition demonstrating a clear radiosensitising effect in an
in vivo tumour growth delay model.
Materials and methods
Cell culture
Tumour cell lines (H460, Calu-6) were cultured in RPMI
1640 medium supplemented with 10% foetal bovine serum
(Sigma). Cultures were maintained at 37 °C and 5% CO2
and were routinely tested for mycoplasma using MycoAlert
testing kit (Lonza). All cell lines were acquired from the
American Type Culture Collection and those grown beyond
4 months after purchase were regularly authenticated by
short tandem repeat profiling (DNA Diagnostics Centre).
Reagents
Mouse monoclonal anti-PBK (TOPK) was purchased from
Sigma (SAB5300406). Anti-RPA70 (ab79398), RPA32
(76420), CldU (ab6326), γH2AX (phospho-Ser139;
ab18311), Cyclin A2 (ab32386), Cyclin E1 (ab133266) and
PBK (phospho-Thr9; ab194953) antibodies were from
Abcam. Antibodies targeting the phospho-HpTGEKP motif
were from Millipore (ABE319). Anti-BrdU/IdU was from
BD Biosciences (BD347580), and CHK1 (Total; #2360),
CHK1 (phospho-Ser345; #2348), Cdc25C (Total; 4688)
and Cdc25C (phospho-Ser216; 4901) antibodies were from
Cell Signalling Technology. Alexa Fluor conjugated goat
anti-mouse, anti-rat and anti-rabbit antibodies were from
Invitrogen. Unless otherwise stated, all other reagents were
from Sigma.
In vivo experiments
H460 (0.5 × 106) or Calu-6 (1 × 106) lung cancer cells were
inoculated subcutaneously with matrigel (BD Biosciences)
in CD-1 nude female mice at age 55–70 days. Animals were
randomly assigned to each treatment group using a random
number generator (EXCEL), but experiments thereafter were
not blinded. A sample size of six mice per group was used
and was calculated to have 90% power (standard deviation
(SD) 25%, alpha 0.05) to detect an 80% difference in tumour
volume, based on G*Power 3.1 [12] and our previous
experience. Once xenografts had reached 100mm3, mice
were treated with Vehicle (5% DMSO/40% PEG400) or
20 mg/kg OTS964 via intraperitoneal injection on days
0 and 2. For the radiation treatments, fractionated doses of
2 Gy/dose were delivered to tumours on days 0, 1 and 2 with
a Gulmay-320 cabinet irradiator (Gulmay) at a dose rate of
2.0 Gymin−1, using lead shielding. The project licence
covering the animal work (PPL30/3395) was approved by
the Oxford University Animal Welfare and Ethical Review
Body and granted by the UK Home Office Animals in
Science Regulation Unit under the Animals (Scientific Pro-
cedures) Act 1986.
Transfection
Ambion Silencer Select siRNAs (Life Technologies) were
transfected into cell lines using RNAiMAX transfection
reagent (Invitrogen) at a concentration of 20 nM according
to the manufacturer’s instructions. Experimental protocols
were initiated 48–72 h following transfection, and knock-
down (KD) efficiency was confirmed at the time of irra-
diation treatment by immunoblotting. The siRNAs used for
this study have been published previously and have
demonstrated effective TOPK KD without producing off-
target effects [10].
Colony formation assays
Cells were plated as single cell suspensions and left to
attach for 8 h prior to irradiation. Colonies were grown for
7–14 days, stained with crystal violet and counted using an
automated GelCount plate scanner (Oxford Optronix). The
plating efficiency (PE) [PE=Average Colony Number/
Cells plated] and the surviving fraction (SF) at a given IR
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dose was calculated using [SF= PEIR Dose/PE0Gy]. The
sensitisation enhancement ratio at an SF of 0.10 (SER10)
was determined by linear quadratic modelling of survival
data. The significance of differences between curves was
calculated by two-way ANOVA, with survival as the
dependent variable and irradiation doses and treatment
conditions as the two independent variables.
Drug treatment and irradiation
OTS964 (OncoTherapy Science, Inc.) and Nocodazole
(Sigma) were dissolved in DMSO and used at concentra-
tions stated. Hydroxyurea (HU; Sigma) was dissolved in
water and used at a concentration of 1 mM unless otherwise
stated. Irradiation for in vitro experiments was delivered at a
dose rate of 1.938 Gy × min−1 using a GSR D1 caesium-137
irradiator (Gamma Service).
Co-immunoprecipitation
Proteins were extracted from precleared whole-cell lysates
prepared in RIPA lysis buffer (Thermo Scientific) with
protease inhibitors (Roche) and phosphatase inhibitors
(Sigma) by incubation with 25 μL of Protein A/G beads
(Santa Cruz) preloaded with 2 μg of antibody for 5–6 h at
4 °C. Immunoprecipitated proteins were released from the
beads by boiling in LDS sample buffer, and analysed by
western blotting.
Immunoblotting
Cell lysates were prepared in RIPA lysis buffer (Thermo
Scientific) with protease inhibitors (Roche) and phosphatase
inhibitors (Sigma) and protein concentration was deter-
mined using the BCA assay (Thermo Scientific). Proteins
were separated by SDS-PAGE and transferred to PVDF
membranes, which were probed by overnight incubation at
4 °C in primary antibody solution. Targets were detected via
HRP-conjugated secondary antibodies exposed to chemi-
luminescence reagent (Millipore).
Fluorescence microscopy
Cells were grown on coverslips at subconfluent densities
and treatments initiated during logarithmic growth phases.
At the relevant time points, nonchromatin bound nuclear
protein was removed by preincubation of coverslips with
CSK extraction buffer (100 mM NaCl, 300 mM Sucrose,
3 mM MgCl2, 10 mM PIPES (pH 7.0), 1 mM EGTA, 0.5%
Triton X100) for 10 min on ice, after which samples were
fixed with 4% paraformaldehyde for 15 min. Coverslips
were blocked before incubation with primary antibody for
3 h, followed by the corresponding fluorescent secondary
antibodies for 1 h at room temperature. Nuclei were coun-
terstained with 0.5 μg/ml 4′,6-diamidino-2-phenylindole
(DAPI; Sigma), and coverslips were mounted using Vec-
tashield (Vector Laboratories). Z stack images were ran-
domly acquired under identical parameters with a Zeiss
LSM710 fluorescence microscope (Zeiss) using a ×63
objective for γH2AX, bromodeoxyuridine (BrdU) and RPA
foci assessment (>10 fields per sample). Nuclear BrdU,
γH2AX and RPA foci number were analysed using ImageJ
software.
DNA fibre assays
Cultured cells were incubated for 30 min with media con-
taining IdU (25 mmol/L) followed by PBS wash and incu-
bation with media containing CldU (250 mmol/L) for
30 min. Cell suspensions were pipetted onto glass micro-
scopy slides and lysed for 10 min. DNA fibres were stret-
ched by raising slides to an angle of 45° after which the
samples were fixed overnight in acetic acid/methanol
solution. Fibres were washed in PBS and denatured in 2N
HCl followed by immunostaining. IdU was detected using
anti-BrdU (mouse) primary antibody (BD) and Alexa
Fluor488 anti-mouse secondary antibody (Invitrogen).
CIdU was detected using anti-BrdU (rat) primary antibody
(Abcam) and Alexa Fluor647 anti-rat secondary (Invitro-
gen). Images (>20 per condition) were randomised and
obfuscated using ImageJ software prior to measurement.
Flow cytometry
Cells were incubated with 20 μM BrdU for 30 min and then
left unirradiated or exposed to 4 Gy IR. Immediately after-
wards, BrdU was removed and cells were returned to 37 °C
and, at different time points, floating and attached cells were
collected together and fixed with ice cold 70% ethanol.
Samples were incubated with 0.1 mg/ml pepsin in 2N HCl
at room temperature in the dark for 20 min. Then, samples
were incubated with mouse anti-BrdU (BD Bioscience) in
1% BSA/PBS for 2 h and with an Alexa Fluor conjugated
secondary anti-mouse antibody for 1 h in the dark. Finally,
samples were incubated with 25 μg/ml propidium iodide
(PI) and 200 μg/ml RNase in PBS for 20 min, and analysed
using FACSCalibur cytometer (Becton Dickson). S-phase
length was determined as described in Begg et al. [13] by
calculating the relative movement (RM) at different time
points after BrdU washout: RM= (FL− FG1)/(FG2/M−
FG1), where FL is the mean PI fluorescence of undivided
BrdU-labelled cells, FG1 is the mean PI fluorescence of the
G1 cells and FG2/M is the mean PI fluorescence of the G2/M
cells. RM values were plotted over time and after linear
curve fitting, the time where RM= 1 (i.e., length of S
phase) was determined.
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Statistical analysis
Statistical analysis and graphs were produced using
GraphPad Prism v8.1.1 (GraphPad Software, San Diego
CA). DNA fibre data are representative of three independent
experiments, with >100 fibres analysed per treatment for
each assay. Foci counting experiments were performed
three times, with >10 randomly assigned fields captured by
confocal microscopy per condition. For colony formation
assays, data are representative of three independent
experiments from triplicate wells, with PE and SER10
(survival enhancement ratio at an SF of 0.10) shown. Data
were analysed by two-way ANOVA, with Bonferroni or
Sidak’s post-tests used for multiple comparisons. Spear-
man’s rank correlation tests were used to assess homo-
scedasticity, and checks were performed for Gaussian
distribution during analysis. Differences were considered
significant at a P value of <0.05, and unless stated, all
results are presented as mean ± SD.
Results
TOPK supports S phase by the protection of
replication fork progression in tumour cell lines
Our previous paper reported that (1) TOPK suppression
increases sensitivity to irradiation in a tumour-specific
manner; (2) TOPK suppression alters G2/M checkpoint
activity in tumour cells by blocking inhibitory phosphor-
ylation of Cdk1; and (3) TOPK suppression promotes
radiation-induced tumour cell death by retaining post-IR
chromosomal damage and increasing the rate of multi-
nucleation following cell division [10]. Our group and
others have observed that whilst many cancers respond to
TOPK treatment, a small subset is resistant. As a con-
sequence, the question of how targeting TOPK differen-
tially sensitised certain tumour cells to irradiation whilst
sparing normal tissue remained.
Cancer cells have fundamental deficiencies in G1/S cell-
cycle checkpoint control, whilst non-carcinogenic cell lines
are checkpoint proficient. This differential characteristic
enables unrestricted proliferation but also creates a potential
(and exploitable) weakness for cancer cells on entry to, and
during, replication—i.e., replication stress [14, 15]. In order
to survive, many tumour subtypes have developed pheno-
types, which provide protection against genomic damage
arising as a consequence of replication stress [1]. Acting
from this background, we questioned whether an increase in
TOPK activity might be providing a protective advantage to
cancer cells with unregulated replicative progression. We
chose to tackle this question by analysing the replication
stress response of a TOPK overexpressing cell line (H460)
when placed under conditions, which disrupted the process
of cellular progression through S phase, and irradiation,
which activated the DNA damage response.
Whilst the role of TOPK as an enforcer of Cdk1 inhi-
bitory phosphorylation in the late G2 phase of the cell cycle
is well established [16], our investigations have also pointed
to a role for TOPK during G1 exit and S-phase progression
[10]. To test the effect of TOPK on S-phase regulatory
control in cancer cells, we depleted TOPK in H460 lung
cancer cells and tracked the process of replication over a 24-
h period by pulsed BrdU labelling. This experiment
revealed that the rate of progression through S phase is
retarded to some extent by ablation of TOPK when com-
pared to non-targeting (NT) controls (Supplementary
Fig. S1a), although the increase in overall S-phase duration
was not significant (Fig. 1a). By incubating cells overnight
with 1 mM HU, we were able to induce mild replication
stress by halting replication fork progression and arresting
cells at the G1/S border. Here, TOPK depletion significantly
reduced the rate of S-phase progression on recovery from
HU treatment (Supplementary Fig. S1a), resulting in a 3 h
increase in the total duration of S phase on average
(Fig. 1a). To consolidate these findings, replication restart
assays were used to assess the role of TOPK in recovery and
completion of replication following HU-induced fork stal-
ling. After release into fresh medium, cycling cells were
captured prior to subsequent cell division with nocodazole.
Using 4N DNA complement as a measure of S-phase
completion, these experiments demonstrated that close to
100% of NT-transfected H460 cells released at the G1/S
border had recovered from fork arrest and completed
replication at the 8 h mark, yet only 50% of TOPK KD cells
had fully progressed through S phase at this timepoint
(Fig. 1b). These results further indicate that TOPK is not
only facilitating the timely progression of cancer cells
through S phase, but also supporting the resumption of
replication at stalled forks.
As radiation is known to arrest replication, we wanted to
assess whether radiation sensitisation in TOPK-depleted
cells could be explained by enhanced recovery from
radiation-induced fork stalling. To this end, we used the
DNA fibre assay, the gold standard assay to monitor fork
speed progression and origin firing. We treated TOPK-
depleted H460 cells with IdU for 30 min, followed by
30 min of labelling with CldU immediately after exposure
to 4 Gy irradiation (n= 4) (Fig. 1c). By comparing incor-
poration of these nucleotide analogues into DNA before and
after irradiation, we were able to gauge whether TOPK KD
influenced DNA replication after radiation. The effect of
radiation on fork progression was significantly greater fol-
lowing TOPK depletion, with an average 50% reduction in
relative fibre length in the 30 min following exposure to 4
Gy, compared to an average 25% reduction in relative fibre
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length measured for controls (Fig. 1c and Supplementary
Fig. S1b). Additionally, firing of new origins doubled in the
TOPK-ablated population following irradiation (Fig. 1c)—a
finding which points to increased endogenous replication
stress and altered regulatory control of the S-phase check-
point control in these cells.
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TOPK suppression increases irradiation-induced
single-stranded DNA (ssDNA) foci
Replication fork stalling and 5′-3′ DNA-end resection dur-
ing double-strand break (DSB) repair can lead to the
exposure of single stranded (ssDNA) [17, 18]. To assess
whether TOPK depletion affects the accumulation of
ssDNA, we incubated cells with BrdU for 48 h to allow
genomic incorporation for all cells prior to irradiation and
stained fixed cells with anti-BrdU under non-denaturing
conditions to identify ssDNA regions produced during
recovery from irradiation damage. Indeed, nuclei of TOPK-
depleted cells retained more than twice as many BrdU foci
on average when compared to those with non-targeting
siRNA at 4 h following irradiation (4 Gy) (Fig. 2a).
To investigate only the ssDNA foci arising from resec-
tion during DSB repair (cells predominantly in G2), S-phase
cells were excluded from analysis. H460 cells were cultured
with IdU-containing media to allow subsequent detection of
focal nuclear regions of ssDNA, and DNA was labelled
with CldU in the 30 min prior to harvest, to identify cells in
S phase. TOPK depletion resulted in more radiation-
induced ssDNA foci in non-S-phase cells (Fig. 2b), sug-
gesting that TOPK depletion leads to more DNA resection.
TOPK-depleted cells also produced five to six times more
ssDNA foci during S phase, indicative of increased repli-
cation fork stalling in TOPK-depleted cells with and with-
out exogenous DNA damage (Fig. 2b). Together these
results suggest that TOPK plays a role during S phase,
enabling cells to cope with replication stress.
Regions of ssDNA generated during replication fork
collapse and IR-induced DNA damage are stabilised by the
RPA complex, which, alongside Rad52, enables Rad51
filament formation [19, 20]. Using RPA70 (RPA 1) as a
marker for post-IR ssDNA, the impact of TOPK depletion
on RPA foci formation and resolution in irradiated H460
cells was quantified by confocal microscopy. The kinetics
of RPA foci formation following 4 Gy IR exposure was
significantly altered by TOPK KD, with a doubling of
average foci/cell at 6 h post-IR and failed resolution at 24 h
(Supplementary Fig. S2a). In fact, RPA foci were still
retained in TOPK-suppressed cells after 48 h or even at 72 h
after irradiation (Fig. 2c).
Protection of ssDNA by RPA binding is critical to the
maintenance of genome stability. Conditions that impair
RPA recruitment or that exhaust the available RPA pool
leave regions of exposed ssDNA vulnerable to breakage and
the generation of single-strand break and DSB [21, 22].
Data from these experiments indicate that TOPK suppres-
sion causes a greater degree of intrinsic replication damage,
but that it is the retention of irradiation-induced damage in
combination with reduced tolerance for replication stress,
which is contributing to radiosensitisation.
TOPK promotes radioresistance via S-phase-
mediated DNA damage signalling
In the presence of IR-induced DNA damage, RPA binding
recruits ATR to DNA lesions and promotes RPA32 phos-
phorylation at serine residues 4 and 8 [23]. RPA32 phos-
phorylation marks the culmination of sequential
phosphorylation by ATR, ATM and DNA-PK [24, 25], and
is widely regarded a marker for replication checkpoint
activation in response to DNA damage [20]. Our observa-
tion of a small, but consistent increase in the population of
TOPK-suppressed cells with >5 pRPA32 (S4/S8) foci in the
24–72-h period after irradiation (Fig. 3a) supports evidence
of functional DNA repair activity, and corresponds with the
increase in total RPA foci seen in Fig. 2c. Localisation of
hyperphosphorylated RPA32 foci to stalled and collapsed
replication forks is known to directly correlate with DSBs
formed as a consequence of DNA damage-induced repli-
cation stress [25]. Unlike DSBs directly attributable to IR,
Fig. 1 TOPK facilitates S-phase progression in cancer cell lines.
a Analysis of S-phase progression through BrdU pulse-chase labelling.
Transfected H460 cells (non-targeting (NT) and siTOPK) were
untreated (top) or synchronised at the G1/S border by overnight
exposure to 1 mM hydroxyurea (bottom) followed by a 30 min pulse
of BrdU. Progression through S phase was determined by cytometric
analysis of BrdU-positive cells. Relative fraction of BrdU negative
cells in G1 (black) or G2 (red) phase, and BrdU-positive cells in early
(S1: BrdU+/2N), mid (S2: BrdU+/>2N to <4N) and late (S3: BrdU
+/4N) S phase is shown as a percentage of the total population at 4, 6,
8 and 24 h post-BrdU uptake. Bar graph indicates analysis of S-phase
duration calculated from mean propidium iodide (PI) fluorescence in
the BrdU-positive population for each condition, using two-way
ANOVA with Bonferroni post-tests; ns= not significant, *p < 0.05.
Immunoblot image is presented to confirm knockdown efficiency.
b Replication restart analysis. Recovery from overnight treatment with
1 mM hydroxyurea (HU) and progression to G2 was assayed in
transfected cells following release into medium containing 100 ng/ml
nocodazole. Samples were analysed at 4, 6 and 8 h post-release for 4N
DNA content by flow cytometry using propidium iodide (PI) staining.
Results from hydroxyurea pretreated samples were standardised rela-
tive to corresponding asynchronous samples incubated in 100 ng/ml
nocodazole from the time of release. Graph shows the mean 4N
population from three independent experiments for each condition,
using two-way ANOVA with Bonferroni post-tests; ****p < 0.0001.
Representative PI plots are shown. c Replication fork progression
using DNA fibre analysis. Control (NT) and siTOPK transfected H460
cells were sequentially labelled with IdU (30 min) followed by CldU
(30 min) before harvesting for DNA fibre analysis. Irradiation (4 Gy)
was performed immediately prior to washout and addition of CldU-
containing medium. Average fibre length and number of new repli-
cation origins were analysed for each condition. Fibre length data were
analysed by two-way ANOVA with Sidak’s multiple comparisons test
(****p < 0.0001). Data are representative of three independent
experiments, with >100 fibres analysed per treatment for each assay.
Percentage replication origins were compared using two-way ANOVA
(not significant (ns); **p < 0.01) with Sidak’s multiple comparisons
post-test (*p < 0.05). Treatment schematic and representative images
of DNA fibres are shown.
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these lesions which comprise an accumulation of secondary
DSBs formed during replication and in association with HR,
are irreparable, and lead to cellular senescence [26].
Furthermore, when TOPK-depleted cells were subjected to
increased replication stress (by HU pretreatment), irradia-
tion produced a marked increase in the presence of γH2AX
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foci during the 24-h post-IR period when compared to NT-
transfected cells (Supplementary Fig. S2b). TOPK depletion
in combination with HU treatment was also associated with
an increase in cells displaying diffuse pan-nuclear γH2AX
staining. Nuclear-wide formation of γH2AX occurs during
catastrophic replication stress, and invariably precedes
irreversible cell death [27].
RPA32 phosphorylation stimulates G2/M checkpoint
arrest via CHK1 [24]. ATR-mediated activation of CHK1 at
serines 317 and 345 triggers a signalling cascade which
regulates S-phase progression and G2/M checkpoint acti-
vation through inhibitory interactions with Cdc25 family
proteins and Cdk1 and 2 [28, 29]. Failure to mount an
effective G2/M checkpoint response increases unresolved
DSBs and γH2AX foci as a consequence of DNA damage
and replicative stress [30], which causes chromatid
exchanges and triggers mitotic catastrophe. Hence from a
mechanistic standpoint, we reasoned that the higher degree
of DNA damage foci retained in TOPK-depleted cells when
exposed to replication stressors and/or irradiation damage
might be linked to changes in activity and expression of S-
phase checkpoint signalling intermediates downstream of
ATR. In control cells, HU treatment stimulated CHK1
phosphorylation at Ser345, and activated the G2/M check-
point within 8–24 h of release (phospho-Cdc25C Ser216)
(Supplementary Fig. S3). Suppression of TOPK weakened
phosphorylation of both CHK1 and Cdc25C after exposure
to HU alone and when combined IR, indicating that S-phase
and G2M checkpoints are impaired for proliferating cancer
cells in the absence of TOPK (Supplementary Fig. S3).
Considering the delayed and persistent nature of post-IR
DNA damage measured in TOPK-depleted cells, we next
considered the relationship between clonogenicity, TOPK
expression and radiation resistance under conditions of repli-
cation stress. Here, colony formation assays were performed
on cells, which were irradiated whilst in a state of HU-induced
replication stress, or following an 8-h period of recovery.
Irradiation of cells under conditions of increased replication
stress enhanced radiation sensitivity for either NT- or TOPK-
transfected H460 cells (SER10
NT= 1.25), with greater radio-
sensitisation observed with TOPK KD (SER10
TOPK= 1.63).
For cells given 8 h of recovery time prior to irradiation,
the radiosensitising effect of HU pretreatment was lost
(SER10
NT= 0.96, SER10TOPK= 0.91) (Fig. 3b). This experi-
ment demonstrated clearly the relationship between TOPK
expression, sensitivity to radiation-induced DNA damage and
replicative stress in the H460 cell line.
To further assess the role of TOPK kinase activity on
checkpoint signalling, we used pharmacological inhibition,
rather than ablation, for subsequent experiments. Dose-
response and colony formation assay experiments demon-
strate that the TOPK inhibitor compounds OTS964 and
OTS514 both sensitise H460 cells to irradiation within the
nanomolar range (Supplementary Fig. S4). A decision was
made to use OTS964 exclusively for this study due to its
more attractive pharmacokinetic profile for in vivo work.
Cells were synchronised at the G1/S border by double
thymidine block and TOPK was inhibited with OTS964. On
release, TOPK-inhibited cell lysates showed significant sup-
pression of phospho-Cdc25C, and partial reduction of CHK1
phosphorylation (Fig. 3c). This downregulation of CHK1 and
Cdc25C phosphorylation also occurred in TOPK-ablated cells
after G1/S synchronisation/release using HU (Supplementary
Fig. S3). Furthermore, TOPK co-immunoprecipitates with
Cdc25C and CHK1 (Fig. 3d). This interaction was observed in
untreated controls as well as in cells following irradiation-
induced DNA damage, populations synchronised in G1/S by
HU, or those synchronised in G2/M by nocodazole treatment.
Additionally, synchronised H460 cells did not demonstrate any
significant change in activation of upstream DNA damage
response intermediates (ATM autophosphorylation, ATR
phosphorylation or DNA-PKcs phospho-activation) with
TOPK KD following irradiation. Nor did we detect any co-
immunoprecipitation between TOPK and ATM, ATR or DNA-
PKcs before, or after OTS964 treatment (data not shown).
Fig. 2 TOPK knockdown suppresses recovery from replication
stress and radiation damage. a Radiation-induced ssDNA foci ana-
lysis. TOPK-ablated H460 cells were grown on coverslips and treated
with BrdU for 48 h. Coverslips were exposed to 4 Gy irradiation, at
which point the growth medium was replaced. After a 4-h recovery
time, cells were fixed for immunocytochemical analysis. Slides were
prepared from stained coverslips and microscopic images were
assayed for presence of BrdU-positive ssDNA foci using DAPI as a
counterstain. At least ten fields of view were used per condition and
results were analysed by two-way ANOVA with Sidak’s multiple
comparisons post-test (ns (not significant); ****p < 0.0001). Scale bar
= 10 μm. b Radiation-induced ssDNA foci analysis with discrimina-
tion between non-S and S-phase cells. Coverslips bearing non-
targeting siRNA (NT) or TOPK-ablated H460 cells were pretreated
with IdU prior to 4 Gy irradiation followed by 30 min CldU incubation
as indicated by the treatment schematic. Coverslips were stained for
non-denatured ssDNA foci (ldU, red) prior to re-staining for CldU-
positive S-phase cells (green) after fixing and denaturing DNA by brief
exposure to DNase (30 min, 10U). Images were captured and assayed
for ssDNA foci in non-replicating nuclei by excluding CldU-positive
S-phase nuclei from analysis. Representative images are shown. Each
experiment was performed three times, and >10 randomly assigned
fields were captured by confocal microscopy per condition. Non-S-
phase graphs represent percentage of cells bearing >5 ssDNA foci/
nucleus for each condition, and S-phase graphs represent average foci/
cell. Results were analysed by two-way ANOVA (ns (not significant))
with Sidak’s multiple comparisons post-tests (****p < 0.0001). Scale
bar= 10 μm. c Accumulation of RPA70 foci in TOPK-ablated cells
after irradiation. H460 cells were siRNA transfected and plated on
coverslips and fixed at 24, 48 and 72 h following irradiation (4 Gy).
Slides were stained for RPA70, and images from ten randomly
assigned fields were captured by confocal microscopy per condition.
Images were analysed for presence of RPA foci using DAPI as a
nuclear counterstain. Results were analysed by two-way ANOVA with
Sidak’s multiple comparisons post-tests (ns (not significant); *p <
0.05; ***p < 0.001). Scale bar= 10 μm.
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In light of these results, our experiments support a role
for TOPK as a mediator of S-phase progression and post-
replication responses via CHK1 and Cdc25C phospho-
activation. These data imply that not only does TOPK
facilitate mitotic progression at the G2/M checkpoint via
Cdk1, but TOPK is also in response to replication stressors
Targeting TOPK sensitises tumour cells to radiation-induced damage by enhancing replication stress 1341
(such as HU treatment or irradiation) by influencing the
action of key intermediates such as CHK1.
TOPK inhibition potentiates fractionated
radiotherapy in vivo
To expand on our in vitro findings, and to investigate the
preclinical validity of TOPK as a therapeutic target, we used
in vivo studies to test the efficacy of OTS964 on sub-
cutaneous xenografts in combination with radiation therapy.
To assess the radiosensitisation efficacy of the OTS964
compound, we performed colony formation assays in H460
and Calu-6 lung cancer cell lines. Both cell lines showed
significant radiosensitisation using a 24 h incubation with
20 nM OTS964 (Fig. 4a and Supplementary Fig. S5a). A
fractionated dosing strategy for irradiation treatment was
found to improve radiosensitisation by OTS964 at this
concentration (Fig. 4b), and so this fractionated radiation
regime was adopted for in vivo studies.
For growth delay experiments, CD-1 nude mice were
inoculated subcutaneously with H460 cells and when
xenografts reached 80 mm3, tumours were irradiated at 2 Gy
for 3 consecutive days. OTS964 was administered at 20 mg/
kg by intraperitoneal injection 1 h prior to irradiation on
days 0 and 2. Tumour growth was almost completely sup-
pressed for 20–30 days in the group which had undergone
combined drug/irradiation treatment; whilst those which
received OTS964 or fractionated irradiation alone had
tumour growth comparable to the vehicle only treated
group, reaching a volume of 500 mm3 within 10 days (n= 6
for each condition) (Fig. 4c). Of the mice in the combina-
tion group, two had tumours which failed to reach 500 mm3
during the course of the experiment (Fig. 4d; P= 0.0067).
A comparable delay in tumour growth was also observed
combining fractionated irradiation with OTS964 in Calu-6
lung cancer xenografts (Supplementary Fig. S5b).
Weight loss was not observed in CD-1 nude mice exposed
to OTS964 at 20mg/kg (Fig. 4f), however, analysis of blood
samples showed a significantly lower total white blood cell
(WBC) count 24 h following administration (Fig. 4e). Daily
analysis of WBC count revealed complete recovery had
occurred 8–10 days following the onset of treatment (Sup-
plementary Fig. S5c). Treatment-associated leukocytopenia
was primarily associated with suppression of the relative
lymphocyte and granulocyte populations, which had resolved
2 weeks later (Supplementary Fig. S5d). This is most likely to
reflect the previously documented influence of OTS964 on
haematopoietic stem cell differentiation to CD41+ mega-
karyocytes, with a concomitant suppression of alternative
lineages [31]. Although the fractionated irradiation schedule
produced a small, but significant shift in the relative lym-
phocyte and granulocyte populations, this was not reflected in
the total WBC count, and did not produce any additive effect
when combined with OTS964 treatment.
Our in vivo findings indicate that inhibition of TOPK
provides a synergistic radiosensitising effect on tumour cell
death, with transient leukocytopenia resulting from treat-
ment. The conclusion from these observations is that sys-
temic administration of OTS964 preferentially affects
tissues with high proliferative turnover, increasing efficacy
for treatment strategies which specifically deliver DNA-
damaging agents to the tumour.
Discussion
Carcinogenic transformation promotes mutational change
that confers a protective advantage, or resistance, to geno-
mic damage occurring during replication—hence the recent
interest in potential drug candidates that interfere with
Fig. 3 TOPK modulates radiosensitivity by interaction with
replication checkpoint signalling intermediates. a Accumulation of
pRPA32 foci in TOPK-depleted cells after irradiation. TOPK-ablated
H460 cells were plated on coverslips and fixed at 0, 8, 24, 48 or 72 h
following irradiation (4 Gy). Slides were stained for RPA32 phos-
phorylated at serine residues 4 and 8, and images from ten randomly
assigned fields were captured by confocal microscopy per condition.
Images were analysed for presence of foci using DAPI as a nuclear
counterstain. Percentage of nuclei with >5 foci for each timepoint was
analysed by two-way ANOVA with Sidak’s multiple comparisons
post-tests (**p < 0.01; ****p < 0.0001) and is representative of two
independently performed experiments. Error bar= SEM. b Effect of
TOPK depletion and replication stress on post-irradiation survival.
TOPK was transiently knocked down with siRNA (siTOPK) in H460
cells. After replating, cells were exposed to hydroxyurea for 16 h, then
irradiated immediately, or at a timepoint 8 h following release. Colo-
nies were stained after 14 days’ growth and analysed for the effect of
replication stress on radiation sensitivity by factorial two-way
ANOVA. Survival curves were fitted using non-linear regression.
Data are representative of three independent experiments and are
presented as mean ± standard deviation (SD) from triplicate wells.
Plating efficiency (PE) and SER10 (survival enhancement ratio com-
pared to NT controls at a surviving fraction of 0.10) are indicated.
Propidium Iodide (PI) cytometry plots of samples taken at the time of
irradiation are shown to indicate cell-cycle distribution. Immunoblot
image is presented to confirm knockdown efficiency. c Suppression of
Cdc25c and CHK1 phosphorylation by the TOPK inhibitor OTS964.
H460 cells were synchronised at the G1/S border by double thymidine
block and treated with OTS964 (20 nM) for 16 h. Following exposure
to 4 Gy irradiation, cells were released into fresh growth medium, and
protein lysates prepared for analysis of phosphorylation status of
Cdc25C and CHK1 at 1, 8 and 24 h post-release. Vinculin was used to
standardise protein loading, and immunoblots of Cyclin A2 and Cyclin
E1 were used to confirm cell-cycle progression. Representative
immunoblots shown (n= 3). d Immunoprecipitation showing inter-
action between TOPK and CHK1 and Cdc25c. TOPK-bound proteins
were extracted from H460 cell lysates following OTS964 treatment
and/or irradiation (4 Gy), overnight treatment with hydroxyurea (HU,
1 mM) or Nocodazole (NOC, 100 ng/ml) by immunoprecipitation.
Pull-down using mouse IgG was used as negative control. Samples
were probed for Cdc25C and CHK1 co-immunoprecipitates by wes-
tern blotting. Immunoblots are representative of three independent
experiments, with 2% input lysate shown for comparison.
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replication and/or enhance replication stress [15]. This study
provides evidence indicating that TOPK is modulating
regulatory control over cell-cycle progression through
events occurring in S phase. The impact of TOPK sup-
pression is particularly prescient to cancer cells, which are
generally exposed to higher replication-associated stress
Targeting TOPK sensitises tumour cells to radiation-induced damage by enhancing replication stress 1343
than surrounding normal tissue. This would also account for
the reduced proliferative turnover of cancer cells measured
by our lab and others after TOPK depletion or inhibition.
Our results show that TOPK interacts with the CHK1
and Cdc25c complex, key players in the replication
damage-induced checkpoint. We showed that, in irradiated
TOPK-depleted cells, replication fork speed slows, origin
firing increases and more regions of ssDNA are formed
compared to TOPK-proficient cells. These responses caused
an accumulation of unresolved RPA and γH2AX foci,
which remain at 72 h after IR. This persistence of RPA foci
at late phase post-IR time points indicates that (1) the pro-
cess of post-damage replication stress is ongoing for TOPK-
ablated cells, and (2) that resolution of single-stranded DNA
in the genome is impaired. Removal of TOPK-mediated
regulatory control precipitates a series of events which
culminate in a higher susceptibility to exogenous DNA
damage. As such, TOPK suppression in combination
radiotherapy has the potential to induce production of post-
replicative DSBs [32]. Although the nature of the interac-
tion between TOPK, CHK1 and Cdc25C remains elusive,
our observations strongly support a model in which upre-
gulation of TOPK in tumour cells plays a vital function
during the increased cellular demands of replication.
Our in vivo experiments were able to demonstrate a
significant delay in tumour growth by OTS964-mediated
TOPK inhibition when used in combination with XRT.
OTS964 has previously been established as a single-agent
anti-cancer drug for a treating variety of cancer subtypes
in vitro, and in vivo when delivered to tumour-bearing mice
at 40 mg/kg (intravenously, bi-weekly for 18 days) or
50–100 mg/kg (oral dosing, daily for 2 weeks) [31]. How-
ever, the high doses of OTS964 used in these studies were
associated with adverse effects. Our study has demonstrated
that when used in combination with fractionated radiation
therapy, a small overall dose of OTS964 (2 × 20 mg/kg) was
able to suppress tumour growth. Although we did see leu-
kocytopenia immediately following exposure, this adverse
effect of OTS964 was transient, with minimal recovery time
afforded by the shorter dosing requirements demonstrated in
our study.
Lin et al. [33] have reported that PBK/TOPK is not an
essential gene for cancer cell survival and that off-target
inhibition of CDK11 by OTS964 contributes to the anti-
proliferation effect of the compound on cancer cell lines.
We have previously demonstrated the non-essential nature
of TOPK for cancer cell survival by using a CRISPR
knockout to create a TOPK-null stable HAP1 cell line [10].
Off-target inhibition of kinases by OTS964 has been previously
reported [31]. Our conclusions regarding the impact of TOPK
on radiation sensitivity and replication stress via interactions
with CHK1 have been based on concomitant use of siRNA KD
experiments as well as through inhibition with OTS964. We
have verified the efficacy of OTS964 as an inhibitor of TOPK
on our cell lines using its substrate motif as a marker (Sup-
plementary Fig. S4c). Importantly, this enabled us to titrate the
concentration of OTS964 used in our investigations to an
effective dose lower than the KD of CDK11 for OTS964
binding, but within the working range for TOPK activity.
Targeting key checkpoint kinases that regulate DNA
replication and repair is seen as a means to introduce tumour-
specific vulnerabilities, which can improve the therapeutic
window for standard treatment modalities [34]. CHK1 inhi-
bition, in particular, is known to slow global replication rates
[35], trigger origin firing [36], increase the phosphorylation of
ATR targets p53, SMC1 and RPA (which increases SSBs and
DSBs) [37], suppress homologous recombination repair [38]
and promote premature mitotic entry through inappropriate
Aurora Kinase activation [39]. However, as CHK1 is
expressed by cancer and normal cells, early clinical trials with
CHK1 inhibitors have been associated with dose-limiting side
effects [40–42]. Our results show that TOPK inhibition sup-
presses CHK1-Cdc25C signalling but, unlike CHK1 inhibi-
tion, the likelihood of toxicity and adverse effects to normal
tissue when targeting TOPK is reduced, as TOPK is only
limitedly expressed in normal tissues.
This paper presents evidence that TOPK plays a supporting
role in CHK1-mediated maintenance of DNA replication
fidelity, and that suppression of TOPK activity and/or
expression disrupts the process of replication such that cancer
Fig. 4 TOPK inhibition enhances tumour sensitivity to fractio-
nated irradiation. a In vitro radiosensitisation by OTS964 in H460
lung cancer cells using a single radiation dose. Cells were plated at
known densities in six-well plates, pretreated with 10 or 20 nM
OTS964 for 1–3 h prior to irradiation, and incubated at 37 °C. Growth
medium was replaced after cells had been exposed to OTS964 for a
total of 24 h, and colony formation assessed after 12 days’ growth.
Survival curves were fitted using non-linear regression. Data are
representative of three independent experiments and are presented as
mean ± standard deviation (SD) from triplicate wells. Plating effi-
ciency (PE) and SER10 (survival enhancement ratio at a surviving
fraction of 0.10) are indicated. b In vitro radiosensitisation by OTS964
using single or fractionated irradiation. TOPK was inhibited in H460
cells using 20 nM OTS964 and cells were exposed to irradiation in a
single dose (4 Gy) or fractionated dosing (3 × 2 Gy, delivered at 24 h
intervals). Colony formation was assessed after 14 days’ growth.
Plating efficiency (PE) was calculated from unirradiated colonies for
each condition, and the surviving fraction of colonies after irradiation
for each treatment group was analysed using two-way ANOVA with
Bonferroni post-tests (ns (not significant); *p < 0.05). c Tumour
growth delay in xenografts treated with OTS964 and fractionated
radiation. CD-1 nude mice bearing H460 tumours were treated with
OTS964 (20 mg/kg; days 0 and 2) and/or irradiation (XRT, 2 Gy; days
0, 1, 2; n= 6). Tumour volume was measured twice-weekly over a 40-
day period. Growth delay data are presented as average tumour
volume. Time for tumours to reach 500 mm3 was analysed by log-rank
survival tests (p= 0.0067; panel (d)). Mice were monitored during the
16-day post-treatment period for blood leucocyte density on days 0, 1
and 14 (white blood cells; WBC) (panel (e); n= 3 per treatment
group), and bodyweight (panel (f)).
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cells are rendered increasingly vulnerable to radiation
damage. Our conclusion is that increased TOPK expression
provides a competitive survival advantage during carcino-
genic transformation by enabling proliferating cells to tolerate
oncogene-induced replication stress. As a potential anti-
cancer target, TOPK would appear to be selective for highly
proliferative cancers with an increased level of endogenous
replication stress, with the efficacy of TOPK inhibitory
treatment being enhanced by delivery in combination with
genotoxic agents. This finding is particularly relevant in light
of our emerging understanding of acquired resistance to
replication-associated stress as an oncogenic survival
mechanism.
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